Open Access

Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders

  • Charlotte M Verolet1Email author,
  • Cécile Delhumeau-Cartier2,
  • Marlène Sartori2, 4,
  • Simona Toma4,
  • Sophie Zawadynski5,
  • Minerva Becker6,
  • Enos Bernasconi7,
  • Laurence Toutous Trellu3,
  • Alexandra Calmy2 and
  • The LIPO Group Metabolism
AIDS Research and Therapy201512:21

https://doi.org/10.1186/s12981-015-0061-z

Received: 3 January 2015

Accepted: 8 June 2015

Published: 20 June 2015

Abstract

Background

Lipodystrophy (LD) is a frequent adverse event of combination antiretroviral therapy (ART) and occurs mainly in patients exposed to first-generation antiretroviral drugs. The aim of this study was to explore and measure the interaction between LD, mental health, and quality of life of human immunodeficiency virus (HIV) positive individuals seen in a metabolic clinic.

Methods

We conducted a single-site cross-sectional study including all HIV-infected patients attending the LIPO group and metabolism day clinic at the University Hospitals of Geneva, Switzerland between January 31, 2008 and November 28, 2013. Data on LD were prospectively collected using the HIV Outpatient Study (HOPS) score, the Lipodystrophy Case Definition (LDCD), ART regimens, anthropometric measures, imaging, and standardized questionnaires. Quality of life was evaluated using a visual analog scale of 0–100. Depression and anxiety were assessed using the Beck Depression Inventory and the State Trait Anxiety Inventory scales, respectively.

Results

One hundred ninety-four patients (54.6% male; 45.4% female; median age, 50 years) on successful ART (median CD4 cell count, 569.0 cells/mm3; median viral load, 20 copies/mL) were evaluated. Among these, 62.7, 63.5 and 35.5% of patients reported at least one body site affected by fat hypertrophy, atrophy or both, respectively. Using the LDCD score conservative definition, including imaging and biological values, 57.8% were diagnosed with LD. Of these, 39.7% suffered from severe/very severe LD. Depression was reported by 35.6% of individuals; 51.9% had anxiety symptoms and 49.5% reported poor quality of life (defined as being inferior to 50% on a scale from 0 to 100%). LD (odds ratio (OR = 5.22, 95% confidence interval (CI) 1.07–25.37, p-value: 0.040), depression (OR = 4.67, 95% CI 1.08–20.31, p-value 0.040), and anxiety (OR = 7.83, 95% CI 1.91–32.03, p-value 0.004) all affected significantly the quality of life.

Conclusions

LD, depression and anxiety were frequent features among HIV-infected individuals seen in the metabolic clinic and significantly impacted on their quality of life.

Keywords

HIV infectionLipodystrophyLipohypertrophyLipoatrophyQuality of lifeMental health disorderDepressionAnxiety

Background

Since the description of the first case of acquired immune deficiency syndrome (AIDS) in 1981, human immunodeficiency virus (HIV) infection has reached pandemic proportions and has continued to expand in worldwide; in 2012 an estimated of 35.3 million of peoples were infected by HIV [1]. Nucleoside reverse transcriptase inhibitors (NRTIs), followed by protease inhibitors (PIs), were the first antiretroviral (ARV) drugs used to treat HIV [2] and succeeded in decreasing mortality by an estimated of 4.2 million of deaths during the previous decade [1, 3, 4]. However, this therapeutic revolution was not without complications as multiple side-effects were associated with these first-generation ARV drugs. Among these, lipodystrophy (LD) was highlighted in 1998 by Carr et al. [5]. This syndrome comprises three phenotypes: lipohypertrophy (LH); lipoatrophy (LA); or a mixed pattern of both [5, 6]. LD can be associated also with metabolic disorders, therefore increasing the risk of cardiovascular disease [7].

There is currently no universal definition of LD. This implies significant variation in the prevalence rate, incidence, severity, and risk factors, which makes difficult any comparison between studies and across countries and ethnicities [7]. Diagnosis is based mainly on clinical observations by the patients themselves and by the physicians. To help meeting this challenge, the HIV Outpatients Study (HOPS) scale provides a subjective, but standardized LD evaluation using specific questions related to the clinical signs of the disorder [8]. Carr et al. developed a score in order to offer a more objective definition of LD, the Lipodystrophy Case Definition (LDCD), with a reported 79% sensitivity and 80% specificity [9, 10]. Nevertheless, this score does not allow differentiating between disease phenotypes [6].

Systematic reviews have discussed the impact of ARV agents and regimens on LD, but with discordant conclusions. If a clear relationship between NRTIs (thymidine analogs) and LA has been demonstrated, the causal role of specific drugs in the development of fat accumulation remains to be clarified [11, 12]. With the advent of newer drugs and the earlier detection of HIV, the prevalence of LD is now decreasing [11], although 48 weeks after the tests of a novel, potent NRTI, BMS-986001 a peripheral and central fat accumulation was observed [13]. However, the overall prevalence of LD remains high as many patients were exposed to first-generation molecules and damage caused to adipose tissue has only limited reversibility [14].

Several research groups have focused on the impact of LD on quality of life [1523]. In addition, these reports have described discrepant results and conclusions regarding the interplay with mental health disorders, such as depression or anxiety [2428].

This study aimed to identify the complex relationships between LD, mental health disorders, and the quality of life in patients attending the LIPO group and metabolism day clinic at the University Hospitals of Geneva, Switzerland.

Methods

Patients

All patients participating to the metabolic clinic (LIPO group and metabolism) at the University Hospitals of Geneva between January 31, 2008 and November 28, 2013 were included in the study. This multidisciplinary consultation (day hospital) is held once monthly and patients are referred to the clinic by their treating physician for several reasons, such as the evaluation of HIV-related or unrelated multiple medical co-morbidities, or LD management. A complete medical check-up is coordinated by the infectious diseases team and includes blood analyses, imaging [body composition and bone dual-energy X-ray absorptiometry (DXA), and thoracic vertebral level (T12) as well as lumbar vertebral level (L5) computed tomography (CT) single slice scans], and psychological, plastic surgery, dermatology, endocrinology, bone diseases and dietary consultations. Physicians from other medical specialties are available upon request e.g., nephrologist, endocrinologist, bone specialist, cardiologist, hepatologist. All patients provided written informed consent and the study protocol was approved by the clinical ethics committee of the University Hospitals of Geneva (CER #09017).

Definitions

LD Patients and physicians both completed a questionnaire based on the HOPS scale [8]. Different parts of the patient body (arms, legs, cheeks and buttocks for signs of atrophy; abdomen, neck and breast for signs of hypertrophy) were evaluated and described as absent, subtle, moderate or severe. The different values were then stratified into five categories (none, all subtle, subtle/moderate, one severe, two or more severe). According to Lichtenstein et al. [8], this score was then classified in two strata; absent vs present and used like this in all the statistical analysis.

We used also the complete model of LDCD score, developed by Carr et al. and validated in a large cohort of patients [9], to determine the categories used to define the presence of LD [10]. LD was stratified in four classes, from very subtle/absent (<0 to 9.9 points) to severe/very severe (15 to >23 points). This score was then classified in two classes; absent (subtle/absent, subtle, moderate) versus present (severe/very severe) and used like this for all the statistical analysis. These definitions are presented in the Additional file 1: Table S1.

Quality of life Patients were asked by a trained psychologist to score their perceived quality of life on a 20 cm quantitative scale ranging from 0 to 100%. Zero corresponds to the “worst possible quality of life” and 100 to the “best possible quality of life”. This measure is often used in cognitive behavioral therapy and is a part of a wider score validated in different studies [29]. In our study, we used the short version of the score. Patients were classified as having a low (0–50%) or high quality of life (51–100%).

Anxiety was evaluated by a trained psychologist using the State Trait Anxiety Inventory (STAI Y-B) grading by a questionnaire with 20 items regarding the trait anxiety developed by Spielberger in 1983 [30]. A score equal or greater than 46 indicated the presence of anxiety symptoms.

Depression was measured by a trained psychologist using the Beck Depression Inventory (BDI) score [31], including a questionnaire with 21 items. Patients were considered to have depression when the score was above 19.

The waist was measured halfway between the last rib and the iliac crest, and the hips by the maximal buttock circumference.

Imaging studies

A CT-scan consisting of two single slices of 6 mm thickness each obtained at the T12 and L5 level was performed in each patient in order to calculate the ratio between the visceral adipose tissue and the subcutaneous adipose tissue (VAT/SAT). Abdominal VAT and SAT were measures by contouring manually the areas with attenuation values of adipose tissue (range 190 Hounsfield Units to 30 Hounsfield Units) according to the literature [32]. Limb as well as leg fat measurement, both needed for LDCD score calculation, was obtained by Total Body Dual X Ray Absorbsometry (DXA) on a Discovery A Bone densitometer (Hologic Inc. Bedford, MA, USA). Total body scans were performed by DXA (Dual X Ray Absorbsometry) using the same Discovery A Bone densitometer all over the study period (Hologic Inc. Bedford, MA, USA). To assure reliability and stability of our device, Phantom was scanned daily; QC (quality control) data plot was verified online by a secured, centralized database program. ISCD (International Society of Clinical Densitometry) recommendations for precision assessment, scans acquisition and analysis are applied.

Statistical analyses

We used a kappa test with an alpha threshold of 5% to measure the level of agreement between patients and physicians regarding the presence of fat loss or accumulation by using the HOPS score. A Chi-square test with an alpha threshold of 5% was used to verify if gender had an impact on qualitative variables (depression, anxiety, quality of life, and LDCD). We conducted a multivariate logistic regression model to identify risk factors for a low quality of life, including the severe LD (LDCD) variable and all other variables with a p value lower than 0.2 in the univariate model, to assess the specific contribution of severe LD (LDCD). To identify specific, potential confounding risk factors of quality of life, such as depression and anxiety, we developed an additional model including clinical risk factors considered to have a potential impact on quality of life in HIV population: age; gender; severe LD (LDCD), atrophy and hypertrophy observed by patients and physicians (HOPS); body mass index (≥30 kg/m2); HIV duration (≥10 years); United States Centers for Disease Control and Prevention HIV stage (B&C); CD4 count (≤300 cells/mm3); and HIV viral load (≥40 copy/mL). Finally, we performed the Hosmer–Lemeshow test, as well as the area under the ROC curve, to evaluate the overall fit of our two logistic regression models. Statistical analyses were carried out with STATA software, version 13.0 (StataCorp, College Station, TX, USA).

Results

Characteristics of the study population

One hundred ninety-four HIV+ individuals were included in the analysis median time since HIV diagnosis was 17 years and a median age of 50 years old [interquartile range (IQR) 44.0–55.0]; 88 (45.4%) were female and 108 (72.5%) were Caucasians (Table 1). Twenty patients (10.4%) were obese with a body mass index ≥30 kg/m2. Almost all patients (99.0%) were on antiretroviral therapy with a majority (88.5%) on nucleoside reverse transcriptase inhibitor (NRTI) treatment. Protease inhibitors (PIs) were used in 50.1% of the patients while 43.7% were taking non-nucleoside reverse transcriptase inhibitor (NNRTI). Among those, 36 (18.6%) were taking efavirenz (EFV), 34 (17.6%) on etravirine and 14 (7.2%) on nevirapine. Eighty-six percent had a viral load below the threshold of 40 copies/mL; median CD4 count was 569.0 cell/mm3 (IQR: 403.0–710.0). Sixty-eight patients (35.6%) reported signs of depression (moderate 23.6%; severe 12.0%). Of them, a psychiatric intervention was indicated in 89.0%, including a psychiatric evaluation in 22.9%, a psychopharmacologic treatment in 33.3%, and a psychotherapeutic treatment in 65.6%. Ninety-nine patients (51.9%) were anxious (moderate 27.8%; severe 24.1%). A psychiatric intervention was indicated in 83.9% of those, including a psychiatric evaluation in 18.3%, a psychopharmacologic treatment in 29.6%, and a psychotherapeutic treatment in 72.3%. However, we do not have the information on whether the patient came or not to his or her appointment. Finally, 93 (49.5%) mentioned poor quality of life (≤50%) (Table 1).
Table 1

Characteristics of the study population

 

N missing

All patients

Quality of Lifea

p-value

Poor (≤50% visual score)

High (>50% visual score)

Median (IQR)

Median (IQR)

Median (IQR)

N = 194

N = 93

N = 95

Patient characteristics

 Sex female, n (%)

 

88.0 (45.4)

50 (53.8)

34 (35.8)

0.013*

 Age (years)

 

50.0 (44.0–55.0)

48.0 (43.0–52.0)

51.0 (45.0–59.0)

0.008*

 Ethnicity

45

   

0.005*

  Caucasians n (%)

 

108 (72.5)

42 (61.8)

62 (82.7)

 

  Africans n (%)

 

29 (19.5)

21 (30.9)

7 (9.3)

 

  Others n (%)

 

12 (8.0)

5 (7.3)

6 (8.0)

 

 Waist/hip ratio

9

0.9 (0.9–1.0)

0.9 (0.8–1.0)

0.9 (0.9–1.0)

0.105

 VAT/SAT ratiob,c

9

0.5 (0.3–1.0)

0.4 (0.2–0.7)

0.5 (0.3–1.1)

0.009*

 Body mass index (kg/m2)d

1

24.0 (22.0–27.0)

24.0 (22.0–27.0)

24.0 (22.0–26.0)

0.547

 Triglycerides (mmol/l)

 

1.3 (0.9–2.2)

1.2 (0.8–1.9)

1.4 (1.0–2.4)

0.252

 Total cholesterol (mmol/l)

 

5.1 (4.4–5.7)

5.0 (4.3–5.7)

5.1 (4.7–5.9)

0.105

 HDL cholesterol (mmol/l)

 

1.2 (0.9–1.4)

1.1 (0.9–1.4)

1.2 (0.9–1.4)

0.795

HIV characteristics

 HIV duration (years)

20

17.0 (11.0–22.0)

15.5 (10.0–21.0)

18.5 (12.0–22.0)

0.099

 CDC HIV stagee

14

   

0.362

  A, n (%)

 

85.0 (47.2)

36.0 (41.9)

46.0 (52.3)

 

  B, n (%)

 

33.0 (18.3)

16.0 (18.6)

15.0 (17.0)

 

  C, n (%)

 

62.0 (34.4)

34.0 (39.5)

27.0 (30.7)

 

 CD4 (cells/mm3)

4

569.0 (403.0–710.0)

612.0 (411.5–752.0)

533.5 (394.0–700.0)

0.116

 HIV viral load (copy/ml)

2

20.0 (20.0–40.0)

20.0 (20.0–40.0)

20 (20.0–40.0)

0.495

 Antiretroviral therapy, n (%)

 

192.0 (99.0)

92.0 (98.9)

94.0 (98.9)

0.988

  Protease inhibitors containing, n (%)

1

97.0 (50.5)

42.0 (46.1)

51.0 (54.3)

0.271

  Integrase inhibitor containing, n (%)

1

41.0 (21.3)

17.0 (18.7)

24.0 (25.5)

0.262

  NRTIe containing, n (%)

1

170.0 (88.5)

83.0 (91.2)

81.0 (86.2)

0.280

  NNRTIf containing, n (%)

1

84.0 (43.7)

42.0 (46.1)

41.0 (43.6)

0.729

  Efavirenz, n (%)

1

36.0 (18.6)

20.0 (22.0)

15.0 (16.0)

0.296

  Etravirine, n (%)

1

34.0 (17.6)

16.0 (17.6)

18.0 (19.1)

0.783

  Nevirapine, n (%)

1

14.0 (7.2)

6.0 (6.6)

8.0 (8.5)

0.622

  Other regimens, n (%)

1

7.0 (3.6)

2.0 (2.1)

5.0 (5.5)

0.230

Questionnaire assessments

 Depression (BDI score)g

3

   

0.001*

  Absent/very subtle (≤10 points), n (%)

 

61 (31.9)

11.0 (11.8)

50.0 (52.6)

 

  Subtle (11–18 points), n (%)

 

62 (32.5)

30.0 (32.3)

31.0 (32.6)

 

  Moderate (19–29 points), n (%)

 

45 (23.6)

31.0 (33.3)

12.0 (12.6)

 

  Severe/very severe (≥30 points), n (%)

 

23 (12.0)

21.0 (22.6)

2.0 (2.1)

 

 Anxiety (STAI-Y-B score)g

3

   

0.001*

  Absent/very subtle (≤35 points), n (%)

 

35.0 (18.3)

3.0 (3.2)

32.0 (34.0)

 

  Subtle (36–45 points), n (%)

 

57.0 (29.8)

19.0 (20.4)

36.0 (38.3)

 

  Moderate (46–55 points), n (%)

 

53.0 (27.8)

34.0 (36.6)

19.0 (20.2)

 

  Severe/very severe (≥56 points), n (%)

 

46.0 (24.1)

31.0 (33.3)

6.0 (6.4)

 

 Lipodystrophy (LDCD score)i

59

    

  Absent/very subtle (≤9.9 points), n (%)

 

57.0 (42.2)

28.0 (46.7)

27.0 (38.6)

0.581

  Subtle (10–14.9 points), n (%)

 

35.0 (25.9)

12.0 (20.0)

22.0 (31.4)

 

  Moderate (15–22.9 points), n (%)

 

12.0 (8.9)

6.0 (10.0)

5.0 (7.1)

 

  Severe/very severe (≥23 points), n (%)

 

31.0 (23.0)

14.0 (23.3)

16.0 (22.8)

 

aQuality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.

bVAT: by CT-scan cross-section of 6 mm, level of L5: intra-abdominal adipose tissue.

cSAT: by CT-scan cross-section of 6 mm, level of L5: extra-abdominal adipose tissue.

dCDC HIV stage: according to CDC Classification System for HIV Infection by the United States Center for Disease Control and Prevention.

eNRTI: Nucleoside reverse transcriptase inhibitors.

fNNRTI: Non-nucleoside reverse transcriptase inhibitors.

gDepression: according to Beck Depression Inventory score by Beck definition (BDI).

hAnxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).

iLDCD: Lipodystrophy Case Definition by Carr et al.

* Significant p-value <0.05.

Prevalence of LD

The prevalence of LD signs and symptoms were assessed using both the LDCD [10] and HOPS scores [8] (Additional file 1: Table S1). The LDCD score diagnosed LD among 57.8% individuals (from subtle to very severe LDCD score). Of these, 39.7% had imaging or biological features corresponding to severe/very severe LD (Table 1). According to the HOPS score, 62.7, 63.5 and 35.5% of patients subjectively reported at least one site affected by fat hypertrophy or atrophy or both, respectively. Patients and physicians were agree on 80.3% (substantial agreement, kappa 0.61; p-value 0.001) regarding the atrophy and on 79.1% (substantial agreement, kappa 0.57; p-value 0.001) regarding the hypertrophy (Table 2). The agreement regarding the atrophy between the two LD tests (HOPS score and LDCD score) was moderate (patients and physicians observations; 55.9 and 48.1% respectively, p-values <0.001 for both). Regarding hypertrophy, the results were not significant (patients and physicians observations (data not shown).
Table 2

Level of agreement between patients and physicians; HIV Outpatient Study (HOPS) score

 

Patients observation

Physicians observation

Agreements (%)

Kappa

p-value

Interpretation

N (%)

N (%)

N = 167

N = 144

Atrophy

106 (63.5)

71 (49.3)

80.3

0.61

0.001*

Substantial

Hypertrophy

106 (62.7)

79 (54.9)

79.1

0.57

0.001*

Substantial

Atrophy/hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.

* Significant p-value <0.05.

Mental health, quality of life, and LD stratified by gender

Women were more likely to present signs of depression or anxiety compared to men (46.0 versus 26.9%; p-value = 0.006; and 62.5 versus 42.7%; p-value = 0.006 for depression and anxiety, respectively) (Table 3). Although there was no gender difference in severe LD according to the LDCD score (p-value = 0.082). Men seem to be more affected by LA, while women suffered mainly from LH according to the HOPS score (Table 3). Moreover, women were more likely to score lower on quality of life than men (59.5 versus 41.4%, respectively; p-value = 0.013).
Table 3

Prevalence of mental health alterations and lipodystrophy symptoms by gender 

 

Male N (%)

Female N (%)

p value

Presence of depression (BDI score ≥19)a

28 (26.9)

40 (46.0)

0.006*

Presence of anxiety (STAI-Y-B score ≥46)b

44 (42.7)

55 (62.5)

0.006*

Poor QoL (≤50% visual score)c

43 (41.4)

50 (59.5)

0.013*

Severe LD (LDCD score ≥23 points)d

21 (28.8)

10 (16.1)

0.082

HOPS score:e

 Atrophy observed by patients

66 (72.5)

40 (52.6)

0.008*

 Atrophy observed by physicians

46 (60.0)

25 (37.3)

0.007*

 Hypertrophy observed by patients

47 (51.1)

59 (76.6)

0.001*

 Hypertrophy observed by physicians

35 (46.7)

44 (63.8)

0.039*

aPresence of depression: according to Beck Depression Inventory score by Beck definition (BDI).

bPresence of anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).

cQuality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.

dSevere LD: according to LDCD score Lipodystrophy Case Definition by Carr et al.

eAtrophy/Hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.

* Significant p-value <0.05.

Factors associated with poor quality of life (QoL)

Among the 188 patients who completed the questionnaire, 93 (49.5%) described a poor quality of life (median (IQR): 40.0 (30.0–50.0) with a visual score of <50% [29]. Although none of the demographic variables was found to be associated with poor quality of life in the multivariate models (M1, M2, Table 4), HIV-related variables, such as duration of HIV diagnosis (categorized by ≥10 years) and the presence of a detectable viral load (categorized by ≥40 copy/mL) both were associated with a poor quality of life; the shorter the time after HIV diagnosis, the worse the quality life (Table 4). Fat atrophy observed by patients and physicians was associated with a poor quality of life in the univariate model, but was no longer statistically significant in the adjusted analyses. Symptoms of depression [M1: OR = 3.62 (95% CI 0.99–13.27); M2: OR = 4.67 (95% CI 1.08–20.31), anxiety features (M1: OR = 7.10 (95% CI 1.99–25.30); M2: OR = 7.83 (95% CI 1.91–32.03)), and severe LD (LDCD) (M1: OR = 6.25 (95% CI:1.33–29.40); M2: OR = 5.22 (95% CI: 1.07–25.37)] were all associated with a poor quality of life in the univariate model (Table 4). They remained statistically significant in both multivariate analyses, apart from depression, which was significantly associated in the second model only (Table 4). No interaction between mental health disorders (depression or anxiety) and LD has been highlighted within the multivariate logistic regression model M2 (data not shown). Finally, we have assumed that the two models are correctly specified with no statistical difference and are in concordance (for M1 and M2, respectively: Hosmer–Lemeshow test: p-value: 0.521 and 0.286; area under the ROC curve 0.847 and 0.863; p-value: 0.338).
Table 4

Risk factors for poor quality of life

 

Poor quality of lifea (≤50% visual score)

Univariate regression

M1: p-value ≤0.2 in univariate model regression

M2: Clinical risk factors

OR (95%IC)

p-values

OR (95%IC)

p-values

OR (95%IC)

p-values

Patient characteristics

 Age (≥50 years)

0.62 (0.35–1.11)

0.109*

1.16 (0.38–3.54)

0.794

1.73 (0.52–5.68)

0.365

 Gender (F)

2.09 (1.16–3.74)

0.014*

1.05 (0.35–3.10)

0.930

1.49 (0.46–4.78)

0.502

 BMI (≥30 kg/m2)b

0.90 (0.53–2.33)

0.828

1.01 (0.14–7.18)

0.988

 Triglycerides (≥2.0 mmol/L)

0.62 (0.33–1.16)

0.135*

0.60 (0.19–1.94)

0.397

  

HIV characteristics

 HIV duration (≥ 10 years)

0.43 (0.21–0.92)

0.030*

0.14 (0.03–0.79)

0.026**

0.10 (0.01–0.63)

0.014**

 CDC HIV stage (B&C)c

1.52 (0.84-–2.77)

0.170*

0.81 (0.27–2.39)

0.697

0.95 (0.30–3.00)

0.936

 CD4 (≤300 cells/mm3)

0.57 (0.20–1.64)

0.300

0.09 (0.01–1.04)

0.054

 HIV viral load (≥40 copy/mL)

2.55 (1.04–6.2)

0.039*

10.4 (1.73–2.55)

0.011**

10.39 (1.79–60.16)

0.009**

 Current use of efavirenz

1.46 (0.69–3.06)

0.316

  

Questionnaire assessments

 Severe LD (LDCD score ≥23 points)d

1.02 (0.45–2.33)

0.949

6.25 (1.33–29.40)

0.020**

5.22 (1.07–25.37)

0.040**

 HOPS score:e

  Atrophy observed by patients

0.51 (0.27–0.99)

0.047*

0.49 (0.12–2.07)

0.334

0.27 (0.05–1.40)

0.120

  Atrophy observed by physicians

0.51 (0.26–1.00)

0.051*

1.13 (0.30–4.26)

0.860

1.47 (0.37–5.84)

0.580

  Hypertrophy observed by patients

1.37 (0.73–2.58)

0.325

0.50 (0.10–2.49)

0.396

  Hypertrophy observed by physicians

0.75 (0.38–1.47)

0.400

0.56 (0.13–2.39)

0.438

  Presence of depression (BDI score ≥19)f

7.33 (3.64–14.77)

0.001*

3.62 (0.99–13.27)

0.053

4.67 (1.08–20.31)

0.040**

  Presence of anxiety (STAI-Y-B score ≥46)g

8.44 (4.37–16.30)

0.001*

7.10 (1.99–25.30)

0.003**

7.83 (1.91–32.03)

0.004**

aQuality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.

bBMI: body mass index (bodyweight in kilogram/(height in meter).

cCDC HIV stage: according to CDC Classification System for HIV Infection used by the United States Center for Disease Control and Prevention.

dSevere LD: according to LDCD score Lipodystrophy Case Definition by Carr et al.

eAtrophy/Hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.

fPresence of depression: according to Beck Depression Inventory score by Beck definition (BDI).

gPresence of anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).

* Significant p-value in univariate model <0.2.

** Significant p-value <0.05.

Discussion

Results of our study indicate a high frequency of LD and mental health disorders among HIV-infected men and women on successful ART presenting at the LIPO group and metabolism day clinic. Almost half of all patients considered themselves as suffering from a poor quality of life. Severe LD, depression, and anxiety were all associated with poor quality of life. This high level of LD frequency is partly due because the patients are referred to the day clinic by their treating physician.

Through these findings, we demonstrate that the objective signs of LD, based on a validated score (LDCD) and including morphologic data and metabolic values, are associated with a decreased quality of life and with the presence of mental health disorders. Fat loss observed by the patient and the physician (HOPS score) was also associated with a poor quality of life, but only in the univariate analysis.

Our results are consistent with several previous studies. First, some authors have highlighted a poor quality of life, severe stigma, and lower values in social and psychological scores regarding HIV-infected patients with or without reported LD [33, 34]. Of note, treatment of mental health disorders improved quality of life [33]. Secondly, other studies emphasized an association between LD and a negative effect on body image [18, 28, 34]. Indeed, because of body changes, stigma remains, leading to poor self esteem [20]. This leads to social isolation [24], decrease of sexual activity [26], and mental health disorders, such as anxiety and depression [35], which contribute to poor quality of life [21]. Guaraldi et al. evaluated LD by three scores, i.e., the Multicenter AIDS Cohort Study score (MACS)-HOPS-LDCD. The results of their study is consistent with our finding that LD is related to a poor quality of life [19]. Similar to other reports, they observed that the presence of LD can lead to ART discontinuation [19, 36, 37]. By contrast, a large study showed that individuals suffering from morphological alterations, such as LD, maintain a good adherence regarding ART [38].

Other studies show discordant results. Quality of life scales and psychological questionnaire often change from one study to another (i.e.: Health Related QoL (HRQoL) [13, 16, 18]; Profil der Lebensqualität Chronischkranker (PLC) [19], HIVspecific QoL [32]) and thus complicates comparison between the targeted population. In addition, study objectives vary (i.e.: cosmetic result, antiretroviral tolerance, global wellbeing, social isolation) and may influence the results. Barata et al. assessed a psychological questionnaire in outpatients with and without LD and found no difference in mental health disorders between the two groups [25]. Rajagopalan et al. found similar results regarding quality of life; however, a subgroup analysis showed that patients with LD, particularly homosexual men and patients undergoing psychiatric treatment, suffered from a low QoL [22].

LD remains a prevalent adverse event, despite the advent of new generation ARV drugs [18]. A recent French observational multicenter study showed that more than half of all patients on long-term effective ART suffer from disturbing and stigmatizing facial lipoatrophy. Congruent with reports from other groups, its prevalence is around 30% in patients who recently started their ARV treatment (1–5 years) [39]; the extent to which signs of LH reflect the physiological aging process is debated [40]. In our cohort, no difference was observed in the prevalence of LA and LH among individuals aged 50 or more and younger patients.

In a recent analysis of 15,275 participants to the Swiss HIV Cohort Study, Keiser et al. describe the suicide rate in HIV patients from 1998 to 2008. Despite a significant decrease rate of suicide between the pre era ARV drugs and the late era, suicides are more frequent in HIV population compared to general population [41]. In 62% of them, mental health disorders, as depression and anxiety, have been highlighted after the HIV diagnosis [41]. HIV infection and its possible impact on mental health can be compared to other chronic diseases, such as diabetes, asthma, or chronic kidney disease [4247]. Indeed, a similar relationship has been highlighted in a recent study showing a major increase of anxiety symptoms as well as depression in patients with chronic obstructive pulmonary syndrome disease [48]. Interestingly, although the symptoms related to pulmonary disease could not be improved, recognition of psychological distress by the physician led to an enhancement of quality of life [48].

This study shows a complex interplay between quality of life, mental health disorders, and signs of LD. Severe LD and mental health disorders were all associated with a subjective impairment of quality of life. Moreover, individuals with a more recent diagnosis (<10 years) or those with a detectable viral load (≥40 copy/mL), more likely due to insufficient adherence to treatment, had also a poor quality of life. Therefore, psychological issues in HIV chronic infection is of major importance for daily constraints associated with the disease, adherence to therapy, and quality of life.

Women were more likely to express signs of depression and anxiety as found in other studies [49, 50]. Depressive symptoms are more than two-fold than those reported in the general population, while the number of men and women patients with anxiety symptoms is multiplied by 2.5 [51]. Men were more likely addressed to our group for LA and women for LH. We may speculate that the acceptability of LA and LH phenotype is gender-influenced.

Our study has some limitations. First, we used a modified quality of life score. This scale registers the self-estimation of the patient within a very specific timeframe. For this reason, a various number of independent variables can interfere with this estimate. We arbitrarily defined poor quality of life as between 0–50 and good quality of life between 51–100 and these thresholds could be challenged. However, this measure is simple to evaluate, and easily repeatable. Moreover, the QoL score that we used in our study has the advantage to be used directly during the clinical interview and measure synthetically the psychic pain in a biopsychosocial situation. As the validated Visual Analog Scale (VAS) largely used for pain appreciation, our QoL scale measure a subjective definition. Secondly, LD assessment remains difficult because of the lack of a gold standard definition. However, we consider that the use of two different scores, one based on the physician and patient perceptions and the other based on objective features, allowed us to capture with sufficient precision the prevalence and the severity of LD in this population. We were able to assess LD with great precision, using multiple and routinely-performed tools during the patient one-day visits to the day hospital. These included 191 of validated questionnaires, representing 98.5% of the patients included in the cohort, and 135 imaging (69.6%) (CT and DXA scans), as well as biological values, which are all features related to the LD. Regarding the HOPS score, there was good concordance between physician and patient assessments for fat atrophy and hypertrophy. Moreover, although the study population represented selected individuals referred by their practicing physician, it included both men and women of diverse ethnicity, thus making our results more consistent.

Conclusions

The majority of the HIV-infected patients seen in the metabolic clinic in Geneva describe, at least, one body site affected by LA or LH and are diagnosed with LD regarding the LDCD score. Depression as well as anxiety feature are also very frequent in our studied population, and, with the presence of LD, are related to a poor quality of life, leading to psycho-social consequences. Mental health and a simple score for quality of life should be routinely assessed among HIV-infected individuals, including those on effective ART, in order to recognize early signs and symptoms of psychological distress and to help patients have better outcomes in their daily life.

Abbreviations

AIDS: 

acquired immune deficiency syndrome

HIV: 

human immunodeficiency virus

NRTIs: 

nucleoside reverse transcriptase inhibitors

NNRTIs: 

non-nucleoside reverse transcriptase inhibitors

PIs: 

protease inhibitors

ARV: 

antiretroviral

ART: 

antiretroviral therapy

LD: 

lipodystrophy

LH: 

lipohypertrophy

LA: 

lipoatrophy

HOPS: 

HIV outpatients study

LDCD: 

lipodystrophy case definition

QoL: 

quality of life

CDC HIV stage: 

CDC Classification System for HIV Infection used by the United States Center for Disease Control and Prevention

DXA: 

bone dual-energy X-ray absorptiometry

CT: 

computed tomography

STAI Y-B: 

state trait anxiety inventory

BDI: 

beck depression inventory

VAT: 

visceral adipose tissue

SAT: 

subcutaneous adipose tissue

CI: 

confidence interval

OR: 

odds ratio

Declarations

Authors’ contributions

AC and CV participated in the project study design. SZ, MB, EB, LTT, MS and ST were involved in data acquisition. CV and CD conducted statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge the support of this work by the members of the day clinic LIPO group and metabolism day clinic at the University Hospitals of Geneva. http://www.lipodystrophy-hug-ge.ch. We thank Rosemary Sudan for editorial assistance.

Funding sources

LIPO Group and Metabolism is sponsored by the Center for Research, University Hospitals of Geneva, SIDAIDE Foundation, AbbVie, Gilead, ViiV Healthcare, Merck Sharpe & Dohme AG, and Janssen-Cilag.

Compliance with ethical guidelines

Competing interest AC received travel grants from Gilead, Boehringer-Ingelheim, Janssen-Cilag.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pediatrics, Children’s Hospital-University Hospitals of Geneva
(2)
HIV Unit, Department of Infectious Diseases, University Hospitals of Geneva
(3)
Department of Dermatology and Venerology, University Hospitals of Geneva
(4)
Department of Psychiatric Diseases, University Hospitals of Geneva
(5)
Department of Nuclear Medicine, University Hospitals of Geneva
(6)
Department of Radiology, University Hospitals of Geneva
(7)
Department of Infectious Diseases, Hospital of Lugano

References

  1. UNAIDS/WHO (2013) AIDS epidemic update: November 2013; http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf. Accessed 15 Jan 2014
  2. H-C Collaboration, Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM et al (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24(1):123–137. doi:10.1097/QAD.0b013e3283324283 View ArticleGoogle Scholar
  3. Fauci AS, Marston HD (2013) Achieving an AIDS-free world: science and implementation. Lancet 382(9903):1461–1462. doi:10.1016/S0140-6736(13)62042-5 PubMedView ArticleGoogle Scholar
  4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13):853–860. doi:10.1056/NEJM199803263381301 PubMedView ArticleGoogle Scholar
  5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7):F51–F58PubMedView ArticleGoogle Scholar
  6. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP (2001) Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 27(5):443–449PubMedView ArticleGoogle Scholar
  7. Calmy A (2003) La lipodystrophie. Rev Med Suisse 2453Google Scholar
  8. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr et al (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15(11):1389–1398PubMedView ArticleGoogle Scholar
  9. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG et al (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case–control study. Lancet 361(9359):726–735PubMedView ArticleGoogle Scholar
  10. Carr A, Law M, Group HIVLCDS (2003) An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33(5):571–576PubMedView ArticleGoogle Scholar
  11. Guaraldi G, Stentarelli C, Zona S, Santoro A (2013) HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 73(13):1431–1450. doi:10.1007/s40265-013-0108-1 PubMedView ArticleGoogle Scholar
  12. de Waal R, Cohen K, Maartens G (2013) Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 8(5):e63623. doi:10.1371/journal.pone.0063623 PubMed CentralPubMedView ArticleGoogle Scholar
  13. McComsey GA (2014) H-1644-HIV NRTI BMS-986001 in Antiretroviral-naïve subjects: evaluation of bone and metabolic safety data through week 48. Abstract ICAAC 2014; http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=36303ae1-2a15-4dd2-a960-f370b3647859&cKey=7f87a869-d8a9-44f4-912d-b46b7c65c5de&mKey=5d6b1802-e453-486b-bcbb-b11d1182d8bb. Accessed 8 Nov 2015
  14. Martinez E (2011) Disorders of fat partitioning in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 25(3):415–427. doi:10.1016/j.beem.2010.10.019 PubMedView ArticleGoogle Scholar
  15. Guaraldi G, Murri R, Orlando G, Squillace N, Stentarelli C, Zona S et al (2008) Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev 10(3):152–161PubMedGoogle Scholar
  16. Guaraldi G, Orlando G, Murri R, Vandelli M, De Paola M, Beghetto B et al (2006) Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res 15(1):173–178. doi:10.1007/s11136-005-8342-y PubMedView ArticleGoogle Scholar
  17. Shenoy A, Ramapuram JT, Unnikrishan B, Achappa B, Madi D, Rao S et al (2013) Effect of lipodystrophy on the quality of life among people living with HIV/AIDS (PLHIV) on highly active antiretroviral therapy. J Int Assoc Provid AIDS Care. doi:10.1177/2325957413488205 PubMedGoogle Scholar
  18. Leclercq P, Goujard C, Duracinsky M, Allaert F, L’Henaff M, Hellet M et al (2013) High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy. AIDS Res Hum Retroviruses 29(5):761–768. doi:10.1089/AID.2012.0214 PubMedView ArticleGoogle Scholar
  19. Guaraldi G, Murri R, Orlando G, Giovanardi C, Squillace N, Vandelli M et al (2008) Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS 22(7):577–585. doi:10.1089/apc.2007.0173 PubMed CentralPubMedView ArticleGoogle Scholar
  20. Power R, Tate HL, McGill SM, Taylor C (2003) A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 79(2):137–141PubMed CentralPubMedView ArticleGoogle Scholar
  21. Rajagopalan R, Laitinen D, Dietz B (2008) Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care 20(10):1197–1201. doi:10.1080/09540120801926993 PubMed CentralPubMedView ArticleGoogle Scholar
  22. Blanch J, Rousaud A, Martinez E, De Lazzari E, Peri JM, Milinkovic A et al (2002) Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr 31(4):404–407PubMedView ArticleGoogle Scholar
  23. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC (2005) Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 19(Suppl 4):S14–S21PubMedView ArticleGoogle Scholar
  24. Casado JL, Iglesias V, del Palacio M, Marin A, Perez-Elias MJ, Moreno A et al (2013) Social isolation in HIV-infected patients according to subjective patient assessment and DEXA-confirmed severity of lipodystrophy. AIDS Care 25(12):1599–1603. doi:10.1080/09540121.2013.793275 PubMedView ArticleGoogle Scholar
  25. Barata A, Malouf J, Gutierrez M, Mateo GM, Sambeat MA, Gich I et al (2013) Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy. Braz J Infect Dis 17(4):444–449. doi:10.1016/j.bjid.2012.11.011 PubMedView ArticleGoogle Scholar
  26. Guaraldi G, Luzi K, Murri R, Granata A, De Paola M, Orlando G et al (2007) Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther 12(7):1059–1065PubMedGoogle Scholar
  27. Crane HM, Grunfeld C, Harrington RD, Uldall KK, Ciechanowski PS, Kitahata MM (2008) Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med 9(9):780–786. doi:10.1111/j.1468-1293.2008.00631.x PubMed CentralPubMedView ArticleGoogle Scholar
  28. Marin A, Casado JL, Aranzabal L, Moya J, Antela A, Dronda F et al (2006) Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res 15(5):767–775. doi:10.1007/s11136-005-5001-2 PubMedView ArticleGoogle Scholar
  29. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L_v2.0_October_2013.pdf. Accessed 15 Jan 2014
  30. Spielberger CD, Gorusch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for State-Trait Anxiety Inventory. Consulting Psychologist Press, Palo Alto, CAGoogle Scholar
  31. Beck ATSR (1988) Carbin MG psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8(1):77–100View ArticleGoogle Scholar
  32. Ferland M, Despres JP, Tremblay A, Pinault S, Nadeau A, Moorjani S et al (1989) Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 61(2):139–148PubMedView ArticleGoogle Scholar
  33. Arseniou S, Arvaniti A, Samakouri M (2014) HIV infection and depression. Psychiatry Clin Neurosci 68(2):96–109. doi:10.1111/pcn.12097 PubMedView ArticleGoogle Scholar
  34. Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M et al (2005) The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 14(4):981–990PubMedView ArticleGoogle Scholar
  35. Tien PC, Barron Y, Justman JE, Hyman C, Cohen MH, Young M et al (2007) Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS 21(5):297–305. doi:10.1089/apc.2006.128 PubMed CentralPubMedView ArticleGoogle Scholar
  36. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P et al (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28(5):445–449PubMedView ArticleGoogle Scholar
  37. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P et al (2001) Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 15(18):2441–2444PubMedView ArticleGoogle Scholar
  38. Guaraldi G, Murri R, Orlando G, Orlandi E, Sterrantino G, Borderi M et al (2003) Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 4(2):99–106PubMedView ArticleGoogle Scholar
  39. Cabrero E, Griffa L, Burgos A, Group HIVBPCS (2010) Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions. AIDS Patient Care STDS 24(1):5–13. doi:10.1089/apc.2009.0191 PubMedView ArticleGoogle Scholar
  40. Guaraldi G, Stentarelli C, Zona S, Santoro A, Beghetto B, Carli F et al (2014) The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. HIV Med. doi:10.1111/hiv.12159 Google Scholar
  41. Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F et al (2010) Suicide in HIV-infected individuals and the general population in Switzerland, 1988–2008. Am J Psychiatry 167(2):143–150. doi:10.1176/appi.ajp.2009.09050651 PubMedView ArticleGoogle Scholar
  42. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG et al (2007) Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21(18):2445–2453. doi:10.1097/QAD.0b013e3282efad32 PubMedView ArticleGoogle Scholar
  43. Jurisic-Erzen D, Benko K, Ljubic S, Jerkovic R (2011) The prevalence of depression and anxiety in seafarers type 2 diabetic patients. Coll Antropol 35(4):1067–1070PubMedGoogle Scholar
  44. Cinar N, Kizilarslanoglu MC, Harmanci A, Aksoy DY, Bozdag G, Demir B et al (2011) Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod 26(12):3339–3345. doi:10.1093/humrep/der338 PubMedView ArticleGoogle Scholar
  45. Takeuchi T, Nakao M, Nomura K, Inoue M, Tsurugano S, Shinozaki Y et al (2009) Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study. Diabetes Metab Res Rev 25(8):762–767. doi:10.1002/dmrr.1041 PubMedView ArticleGoogle Scholar
  46. Trzcinska H, Przybylski G, Kozlowski B, Derdowski S (2012) Analysis of the relation between level of asthma control and depression and anxiety. Med Sci Monit 18(3):CR190–CR194PubMed CentralPubMedView ArticleGoogle Scholar
  47. Lee YJ, Kim MS, Cho S, Kim SR (2013) Association of depression and anxiety with reduced quality of life in patients with predialysis chronic kidney disease. Int J Clin Pract 67(4):363–368. doi:10.1111/ijcp.12020 PubMedView ArticleGoogle Scholar
  48. Yildirim A, Asilar RH, Bakar N, Demir N (2013) Effect of anxiety and depression on self-care agency and quality of life in hospitalized patients with chronic obstructive pulmonary disease: a questionnaire survey. Int J Nurs Pract 19(1):14–22. doi:10.1111/ijn.12031 PubMedView ArticleGoogle Scholar
  49. Dumont IP, Olson AL (2012) Primary care, depression, and anxiety: exploring somatic and emotional predictors of mental health status in adolescents. J Am Board Fam Med 25(3):291–299. doi:10.3122/jabfm.2012.03.110056 PubMedView ArticleGoogle Scholar
  50. Schandl A, Bottai M, Hellgren E, Sundin O, Sackey P (2012) Gender differences in psychological morbidity and treatment in intensive care survivors—a cohort study. Crit Care 16(3):R80. doi:10.1186/cc11338 PubMed CentralPubMedView ArticleGoogle Scholar
  51. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):593–602. doi:10.1001/archpsyc.62.6.593 PubMedView ArticleGoogle Scholar

Copyright

© Verolet et al. 2015

Advertisement